Teriparatide is the 1-34 amino-acid active fragment of human parathyroid hormone. U.S. labels support specific osteoporosis indications in people at high fracture risk; it is not a general bone, recovery or performance product.

Established. Review the research and limitations before relying on this record.

Teriparatide activates the PTH type 1 receptor. Intermittent labelled exposure stimulates bone formation, but PTH biology is context- and exposure-pattern dependent; the mechanism should not be simplified to “builds bone” in every setting.

The cited label reports rapid subcutaneous absorption, peak concentrations near 30 minutes, and serum concentrations becoming non-quantifiable within about three hours. It is cleared by non-specific enzymatic mechanisms with hepatic and extra-hepatic handling.

FDA-approved teriparatide products have specific osteoporosis indications and trial evidence for fracture-risk reduction in their indicated populations. Those results do not establish benefit for athletic injury recovery, healthy bone augmentation or unreviewed combinations.

Labelled cautions include hypercalcaemia, orthostatic hypotension, urolithiasis risk and avoidance in people at increased baseline risk of osteosarcoma. The treatment-duration and eligibility decisions belong to the current label and clinician-led assessment.

This is a source-backed medicine and safety summary, not a recommendation or a protocol. Product labels, approvals, contraindications, interactions and availability differ by jurisdiction; check the current official product information and consult a qualified clinician.